Evommune, Inc.
EVMNNext catalyst
EVO756, Dose 1
Migraine
Get an email about EVMN's next catalysts
Track Evommune (EVMN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
EVMN Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.82 | FQ end Sep/2026 | Call: tbd
EVO756, Dose 1 Phase 2 Est. Readout
Estimated primary completion for EVO756, Dose 1 trial (NCT07616128) in Migraine. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
EVO101
Atopic Dermatitis Eczema
Oral EVO756
Chronic Inducible Urticaria
EVO756
Chronic Spontaneous Urticaria
EVO301
Atopic Dermatitis (AD)
EVO756, Dose 1
Migraine
EVO756, Dose 2
Migraine
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EVO101 | Phase 2 | Atopic Dermatitis Eczema | - | - |
Oral EVO756 | Phase 2 | Chronic Inducible Urticaria | - | - |
EVO756 | Phase 2 | Chronic Spontaneous Urticaria | - | - |
EVO301 | Phase 2 | Atopic Dermatitis (AD) | - | - |
EVO756, Dose 1 | Phase 2 | Migraine | - | - |
EVO756, Dose 2 | Phase 2 | Migraine | - | - |
Frequently asked questions
What is in Evommune, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Evommune, Inc.'s (EVMN) pipeline across Phase 2. Its lead program is EVO756, Dose 1 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Evommune, Inc.'s next FDA catalyst?→
Evommune, Inc.'s (EVMN) next tracked catalyst is a Phase 2 readout expected October 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EVMN biotech catalysts?→
Add EVMN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Evommune, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.